Issue 27, 2025, Issue in Progress

Synthesis of SGLT2 inhibitor O-glucoside derivatives for enhancing anti-heart failure activity

Abstract

SGLT2 inhibitors were derived from the natural product phlorizin and were used clinically to treat heart failure with preserved ejection fraction (HFpEF). In this study, based on phlorizin as the lead compound, tyramine moiety was introduced while retaining the pharmacophoric glucoside, thereby enhancing SGLT2 protein inhibitory activity and improving gastrointestinal absorption properties. We synthesized 11 new O-glucoside derivatives and evaluated their anti-heart failure activities. Results showed that compound D4 significantly increased the inhibition rate of the SGLT2 protein and anti-heart failure activity compared with empagliflozin and phlorizin and increased the ATP content in the impaired cardiomyocytes, which exhibited the best inhibition effect on SOD enzymes. According to the docking scores, it was speculated that compound D4 could treat heart failure by inhibiting cellular oxidative stress and reducing ROS and lipid peroxidation. The pharmacokinetic prediction results showed that compound D4 had good plasma protein binding force and hydrophilicity.

Graphical abstract: Synthesis of SGLT2 inhibitor O-glucoside derivatives for enhancing anti-heart failure activity

Supplementary files

Article information

Article type
Paper
Submitted
10 Jan 2025
Accepted
23 Mar 2025
First published
27 Jun 2025
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2025,15, 21922-21933

Synthesis of SGLT2 inhibitor O-glucoside derivatives for enhancing anti-heart failure activity

Y. Liu, X. Fang, M. Sun, X. Wang, K. Ma, B. Wang, Q. Li, J. M. Omar, Y. Liu, H. Liu and W. Han, RSC Adv., 2025, 15, 21922 DOI: 10.1039/D5RA00235D

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements